BioVie Inc. clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The Company is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Terren Peizer ||19,529,846||
|Cuong Viet Do ||199,054||
|The Vanguard Group, Inc. ||97,021||
|Columbia Management Investment Advisers LLC ||72,280||
|Jonathan Adams ||63,674||
|swisspartners AG ||55,521||
|Steve Gorlin ||50,000||
|Renaissance Technologies LLC ||27,900||
|James D. Lang ||25,044||
|Millennium Management LLC ||23,107||
|Company contact information|
Sector Bio Therapeutic Drugs
Connections : BioVie Inc.